



## DEPARTMENT OF HEALTH & HUMAN SERVICES

---

Food and Drug Administration  
Rockville, MD 20857

June 25, 2020

Eric Gruff, President  
E4 Consulting  
15696 Oakstand Road  
Poway, CA 92064-2264

*Sent via email to:* [eric@e4consult.com](mailto:eric@e4consult.com)

Dear Petitioner:

Your petition to the Commissioner of Food and Drug Administration requesting to determine whether BACTROBAN® (mupirocin calcium) Nasal Ointment, 2%, approved under NDA 050703 (held by GlaxoSmithKline), has been discontinued from sale for safety or efficacy reasons was received by this office on 06/24/2020.

It was assigned docket number FDA-2020-P-1617. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter and in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Karen Malvin  
Supervisory Administrative Proceedings Officer  
Dockets Management Staff  
FDA/Office of Operations (OO)